

**EISAI ANNOUNCES SATISFACTION OF CONDITIONS TO TENDER OFFER**

**About Eisai Co., Ltd.**

Eisai Co., Ltd. is a research-based *human health care (hhc)* company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; gastrointestinal disorders; and integrative oncology, including oncotherapy and supportive-care treatments. Through a global network of research facilities, manufacturing sites and marketing affiliates, Eisai actively participates in all aspects of the worldwide healthcare system.

**About Eisai Corporation of North America**

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

**Forward Looking Statement**

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements regarding the expected timing of the completion of the transaction. Words such as “expects,” “anticipates,” “forecasts,” and similar expressions are intended to identify such forward-looking statements. We will not undertake and specifically decline any obligation to update or correct any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

**Inquiries:**In Japan

Mr. Akira Fujiyoshi  
Vice President  
Corporate Communications &  
Investor Relations  
Phone: +81-3-3817-5120

In the US

Investors:  
Mr. Robert Feeney  
Director, Investor and Government Relations  
Eisai Corporation of North America  
201-746-2069

Media:  
Ms. Judee Shuler  
Director, Corporate Planning & Communications  
Eisai Corporation of North America  
201-746-2241

Sard Verbinnen & Co.  
Jim Barron/Susan Burns/Victoria Hofstad  
212-687-8080

#####